Stepan Company (SCL)
Stepan Reports Third Quarter 2025 Results
Stepan Company (SCL)
Stepan Increases Quarterly Cash Dividend, Marking the 58th Consecutive Year of Increases
Axogen Inc. (AXGN)
Axogen, Inc. Reports Third Quarter 2025 Financial Results
Avalo Therapeutics Inc. (AVTX)
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
Lifecore Biomedical (LFCR)
Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company
XORTX Therapeutics Inc (XRTX)
XORTX Announces Closing of US$1.1 Million Registered Direct Offering
Seres Therapeutics Inc (MCRB)
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155
Fulcrum Therapeutics (FULC)
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
Eli Lilly and Company (LLY)
LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound
Merck & Company Inc (MRK)
Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
Bausch&Lomb Corp (BLCO)
Bausch + Lomb Announces Third-Quarter 2025 Results
Thomson Medical Group Limited (A50)
Merck & Company Inc (MRK)
European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)